血塞通联合常规西药治疗慢性心力衰竭Meta分析

Meta Analysis of Xuesaitong Combined with Conventional Western Medicine in the Treatment of Chronic Heart Failure

目的对血塞通治疗慢性心力衰竭(CHF)的有效性及安全性进行系统评价。方法检索PubMed、维普、中国知网、万方数据库收录的血塞通治疗CHF临床随机对照试验(RCT)文献,筛选文献并提取信息,用软件RevMan 5.3进行Meta分析,GRADE 3.2系统进行质量评价。结果共纳入12篇符合标准的文献,合计1399例研究对象。Meta分析结果显示:联合血塞通治疗的试验组在改善临床疗效、提高LVEF值及6 min步行试验方面均明显优于对照组,在降低LVEDD、NT-proBNP、D-二聚体以及ICAM-1方面均明显优于对照组,并且血塞通安全性较好,未出现严重不良反应。GRADE证据质量评分显示:纳入研究结局指标的证据质量大多数为中级和低级。结论在临床中应用血塞通联合常规西药治疗CHF临床疗效明确,安全可靠,不良反应较少,且与剂型无关。

Objective To evaluate the effectiveness and safety of Xuesaitong in chronic heart failure(CHF).Methods Databases of PubMed,VIP,CKNI,and Wanfang were retrieved for clinical randomized controlled trials(RCT)for CHF.Literatures were screened and information was extracted according to inclusion and exclusion criteria.Mete analysis was performed using RevMan 5.3 software,and quality evaluation was performed using GRADE 3.2 system.Results A total of 12 literatures meeting the criteria were included,with a total of 1399 subjects.The results of meta-analysis showed:The experimental group combined with Xuesaitong was significantly better than the control group in improving clinical efficacy,increasing LVEF value and 6 min walking test,and was significantly better than the control group in reducing LVEDD,NT-proBNP,D-dimer and ICAM-1,and Xuesaitong was safe without serious adverse reactions.The GRADE evidence quality score showed that the quality of evidence included in the outcome measures was mostly intermediate and low.Conclusion The clinical efficacy of conventional western medicine combined with Xuesaitong in the treatment of CHF is clear,safe and reliable,with less adverse reactions,and independent of dosage form.